Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure

Circulation Journal

Volumn 71, Issue 5, 2007, Pages 623-630

  Tamura, Toshihiro ^a   Furukawa, Yutaka ^a   Taniguchi, Ryoji ^a   Sato, Yukihito ^b   Ono, Koh ^a   Horiuchi, Hisanori ^a   Nakagawa, Yoshihisa ^a   Kita, Toru ^a   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

Author keywords

Adiponectin; Brain natriuretic peptide; Congestive heart failure; Mortality

Indexed keywords

ADIPONECTIN; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; LIPID;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE MARKER; ENERGY BALANCE; FEMALE; GLUCOSE METABOLISM; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34247614098     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.623     Document Type: Article

References (44)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350.
3. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010.
4. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
5. Wolf G. Adiponectin: A regulator of energy homeostasis. Nutr Rev 2003; 61: 290-292.
6. Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6: 7-14.
7. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocytederived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
8. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-929.
9. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635.
10. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919; quiz 920.
11. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-1389.
12. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005; 67: 705-713.
13. Steinmetz M, Quentin T, Poppe A, Paul T, Jux C. Changes in expression levels of genes involved in fatty acid metabolism: Upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. Basic Res Cardiol 2005; 100: 263-269.
14. Ding ST, Liu BH, Ko YH. Cloning and expression of porcine adiponectin and adiponectin receptor 1 and 2 genes in pigs. J Anim Sci 2004; 82: 3162-3174.
15. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005; 280: 18341-18347.
16. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43: 174-179.
17. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and. J Nucl Med 2001; 42: 55-62.
18. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
19. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin levels predict outcome in patients with severe congestive heart failure. Heart 2006.
20. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 2006; 70: 1557-1562.
21. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism 2004; 53: 1-3.
22. Valsamakis G, Chetty R, McTernan PG, Al-Daghri NM, Barnett AH, Kumar S. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 2003; 5: 131-135.
23. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
24. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 2004; 43: 1195-1200.
25. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19(Suppl 5): V67-V72.
26. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002; 55: 65-85.
27. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
28. Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002-1008.
29. Johnson G, Carson P, Francis GS, Cohn JN. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II): V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI-32-VI-39.
30. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
31. Cohen N, Gorelik O, Almoznino-Sarafian D, Alon I, Tourovski Y, Weissgarten J, et al. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin Nephrol 2004; 61: 177-184.
32. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
33. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
34. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38: 789-795.
35. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity. J Card Fail 2003; 9: 29-35.
36. Gustafsson F, Kragelund CB, Torp-Pedersen C, Seibaek M, Burchardt H, Akkan D, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: Influence of left ventricular systolic function. Eur Heart J 2005; 26: 58-64.
37. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 2005; 150: 1233-1239.
38. Maruyoshi H, Kojima S, Otsuka F, Funahashi T, Kaikita K, Sugiyama S, et al. Hypoadiponectinemia is associated with coronary artery spasm in men. Circ J 2005; 69: 1154-1156.
39. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 1304-1309.
40. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004; 279: 28670-28674.
41. Matsumura Y, Takata J, Kitaoka H, Kubo T, Baba Y, Hoshikawa E, et al. Long-term prognosis of dilated cardiomyopathy revisited: An improvement in survival over the past 20 years. Circ J 2006; 70: 376-383.
42. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692.
43. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576: 492-497.
44. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-1653.